Conflict of interest: Consultant, Luitpold Pharma
Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia
Version of Record online: 18 JAN 2013
Copyright © 2012 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 88, Issue 2, pages 97–101, February 2013
How to Cite
Bregman, D. B., Morris, D., Koch, T. A., He, A. and Goodnough, L. T. (2013), Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am. J. Hematol., 88: 97–101. doi: 10.1002/ajh.23354
Author Contribution DBB, DM, and TAK designed the research and analyzed the data; DM also performed statistical analysis; LTG designed the research, participated in the analysis of the data, and the writing of the manuscript; AH analyzed the data and generated the initial draft of the manuscript. DBB and TAK are employees of Luitpold Pharmaceuticals, the Sponsor of the study. AH is an employee of St. John's University. DM and LTG are consultants for Luitpold Pharmaceuticals.
- Issue online: 24 JAN 2013
- Version of Record online: 18 JAN 2013
- Accepted manuscript online: 17 NOV 2012 03:06AM EST
- Manuscript Accepted: 15 OCT 2012
- Manuscript Received: 11 OCT 2012
- 11Comparison of high dose carboxymaltose to oral or IV iron in subjects with iron deficiency anemia not suitable for oral iron. Am Soc Nephrol 2011;22:405A., , , et al.
- 12A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182–1192., , , et al.Direct Link:
- 13Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial. Am J Obstet Gynecol 2008;199:435 e431–e437., , , et al.